Xeljanz(tofacitinib)

Rheumatoid arthritis; psoriatic arthritis; ulcerative colitis; juvenile idiopathic arthritis; ankylosing spondylitis. JAK inhibitor.

1 DTP program

From $1,518/mo cash · $0/mo copay card

1 platform

FDA-Approved Indications

Moderately-to-severely active rheumatoid arthritis in adultsActive psoriatic arthritis in adultsModerately-to-severely active ulcerative colitis in adults

Available direct-to-patient (DTP) programs

Sorted by price, lowest first. Always verify eligibility and pricing directly with the manufacturer.

Lowest price option

GoodRx cash + copay card (insured)

via PfizerForAll · Pfizer

$1,518/mo cash · $0/mo copay card

GoodRx cash: $1,518.30 (30 tabs, 65% off retail). Copay card: $0/mo for commercially insured (annual cap $4,000–$15,000).

Eligibility

GoodRx cash: US + PR, valid Rx. Copay card: commercial insurance required. Government beneficiaries excluded from copay card. High cash price.

Some benefits may not be available in: MA, CA

Visit Program

Last verified: Mar 2026

Not sure which Xeljanz program fits your situation?

Find My Options